Canavan Disease clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
A Study of AAV9 Gene Therapy in Participants With Canavan Disease
open to eligible people ages up to 30 months
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Our lead scientists for Canavan Disease research studies include Alexander Fay, MD.